India, May 31 -- Regeneron Pharmaceuticals Inc. (REGN) announced detailed analyses from the Phase 3 C-POST trial, which evaluated PD-1 inhibitor Libtayo (cemiplimab)in patients with high-risk cutaneous squamous cell carcinoma after surgery.
The results include additional data for the primary endpoint of disease-free survival (DFS) and the first presentation of key secondary endpoint outcomes.
The Phase 3 C-POST trial demonstrates that cemiplimab is a highly active therapy in high-risk cutaneous squamous cell carcinoma, with clinically meaningful outcomes across primary and secondary endpoints and exceptionally low rates of locoregional and distant recurrence.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0')...